医药生物行业：上海市脑机接口政策将进一步激活其市场应用空间

Investment Rating - Industry investment rating is maintained at "Overweight" [2] Core Viewpoints - The "Shanghai Brain-Computer Interface Future Industry Cultivation Action Plan (2025-2030)" aims to accelerate disruptive technological breakthroughs and seize development opportunities in brain-computer interfaces, which have broad application prospects in medical, health care, education, and entertainment sectors [2] - The action plan outlines six core areas and 17 specific measures to promote the industrialization of brain-computer interface technology, with goals to achieve high-quality breakthroughs in brain control technology by 2027 and to establish a complete clinical application of brain-computer interface products by 2030 [6][2] - The market potential for brain-computer interface technology is significant, with advancements leading to the emergence of innovative companies in Shanghai, such as Brain Tiger Technology and BoRuiKang, which are developing products in invasive and semi-invasive tracks [6][2] - Policy support from the action plan is expected to lower operational costs for companies and enhance market competitiveness, providing more investment opportunities [6][2] Summary by Sections Industry Performance - Over the past 12 months, the industry has shown a relative return of -27.89% compared to the CSI 300 index, with absolute returns of -14.54% [5] Related Research Reports - The report references several related industry reports that discuss various aspects of the pharmaceutical and biotechnology sectors, indicating ongoing research and development activities [6] Investment Recommendations - The report suggests focusing on the development and production of medical-grade brain-computer interface products, the widespread application of non-invasive technologies, and the collaborative development of upstream and downstream enterprises in the industry chain [6][2]